
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>A Pilot Study of Corticosteroid Treatment for Achalasia‑Variant Esophagogastric Junction Outflow Obstruction  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>A Pilot Study of Corticosteroid Treatment for Achalasia‑Variant Esophagogastric Junction Outflow Obstruction  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Gastro Hep Advances (pre‑proof, 2026)  </li>
<li style="margin-left: 0px;">DOI: https://doi.org/10.1016/j.gastha.2026.100895  </li>
</ul>
<details><summary><strong>1. Article Metadata &amp; Authorship  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Authors: Chanakyaram A. Reddy MD; Ashton Ellison MBchB; Vani J.A. Konda MD; Anh D. Nguyen MD; Rhonda F. Souza MD<em>; Stuart J. Spechler MD</em>  </li>
<li style="margin-left: 0px;">Affiliations: Dept. of Medicine, Center for Esophageal Diseases, Baylor University Medical Center &amp; Baylor Scott &amp; White Research Institute, Dallas, TX  </li>
<li style="margin-left: 0px;"><em>Co‑Senior Authors: R.F. Souza, S.J. Spechler</em>  </li>
<li style="margin-left: 0px;">Correspondence: C.A. Reddy, MD – 3434 Swiss Ave., Suite 200, Dallas, TX 75204; Phone 469‑800‑7050; Email shanreddy13@gmail.com  </li>
</ul>
</div></details>
<details><summary><strong>2. Study Design &amp; Ethical Oversight  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Design:</strong> Prospective pilot trial evaluating prednisone (20 mg daily × 14 days) in EGJOO patients.  </li>
<li style="margin-left: 0px;"><strong>Eligibility:</strong> Adult dysphagia and/or non‑cardiac chest pain; conclusive EGJOO per HRM (CC v4.0), confirmed by esophagram and/or EndoFLIP.  </li>
<li style="margin-left: 0px;"><strong>Exclusions:</strong> Prior foregut surgery, botulinum toxin ≤6 mo, hiatal hernia &gt;2 cm, esophageal mass/stricture, reflux esophagitis LA B‑D, current immunosuppressants or opioids.  </li>
<li style="margin-left: 0px;"><strong>IRB Approval:</strong> Baylor Research Institute Institutional Review Board #022‑001.  </li>
<li style="margin-left: 0px;"><strong>Trial Registration:</strong> ClinicalTrials.gov NCT06588348 (STROBE reporting).  </li>
</ul>
</div></details>
<details><summary><strong>3. Patient Cohort &amp; Baseline Characteristics  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Total enrolled:</strong> 10 patients (mean age 58.2 y; 5 M/5 F).  </li>
<li style="margin-left: 0px;"><strong>Diagnostic confirmation:</strong> 4 by FLIP only, 2 by esophagram only, 4 by both modalities.  </li>
<li style="margin-left: 0px;"><strong>Atopy prevalence:</strong> 9/10 with asthma, eczema, food or seasonal allergy; 2 patients (#3, #10) had EoE (no structural rings/strictures).  </li>
</ul>
<details><summary><strong>3.1 Baseline Testing Summary (Table 1)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Peak eosinophil count:</strong> 0–30 /hpf across subjects; patient 4 showed distal‑only elevation (30 /hpf).  </li>
<li style="margin-left: 0px;"><strong>Esophagram findings:</strong> Liquid retention in patients 1, 5, 7, 8, 9; tablet retention in patients 1, 3, 6, 7, 8, 9.  </li>
<li style="margin-left: 0px;"><strong>FLIP metrics:</strong> Distensibility Index (DI) 0.5–3.5 mm²/mmHg·s; Max diameter 5.1–15 mm.  </li>
</ul>
</div></details>
<details><summary><strong>3.2 Symptom Scores &amp; Manometry (Table 2)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Eckardt scores pre‑Rx:</strong> 2–6 (median 4).  </li>
<li style="margin-left: 0px;"><strong>BEDQ scores pre‑Rx:</strong> 1–26 (median 9.8).  </li>
<li style="margin-left: 0px;"><strong>Supine IRP mean:</strong> 31.4 ± 8.9 mmHg; Upright IRP mean: 26.1 ± 8.5 mmHg.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>4. Intervention &amp; Outcome Measures  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Drug regimen:</strong> Prednisone 20 mg PO daily × 14 days.  </li>
<li style="margin-left: 0px;"><strong>Assessments:</strong> Allergy/atopy questionnaire, Eckardt score, BEDQ, repeat HRM on day 14; all within ≤18 months of baseline HRM.  </li>
</ul>
<details><summary><strong>4.1 Symptom Change Post‑Prednisone  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Eckardt improvement:</strong> 6/10 patients ↓; mean change 3.5 → 3.2 (p=0.315, NS).  </li>
<li style="margin-left: 0px;"><strong>BEDQ improvement:</strong> 8/10 patients ↓; mean change 9.8 → 8.2 (p=0.385, NS).  </li>
<li style="margin-left: 0px;"><strong>Best responder:</strong> Patient 10 (atopy + EoE) – greatest symptom drop.  </li>
<li style="margin-left: 0px;"><strong>Worst responder:</strong> Patient 6 (no atopic history) – minimal improvement.  </li>
</ul>
</div></details>
<details><summary><strong>4.2 Manometric Change Post‑Prednisone  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Supine IRP:</strong> ↓ to 22.9 ± 7.7 mmHg (p=0.02).  </li>
<li style="margin-left: 0px;"><strong>Upright IRP:</strong> ↓ to 21.7 ± 8.5 mmHg (p=0.03).  </li>
<li style="margin-left: 0px;"><strong>IRP normalization:</strong> Achieved in only patient 2; others remained above normal despite reductions.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>5. Pathophysiological Rationale  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Hypothesis:</strong> Subset of achalasia/EGJOO driven by type 2 (allergic) inflammation in esophageal muscle.  </li>
<li style="margin-left: 0px;"><strong>Mechanism proposed:</strong> Eosinophils/mast cells infiltrate LES muscle → release cytotoxins → neuronal injury → impaired LES relaxation.  </li>
</ul>
<details><summary><strong>5.1 Supporting Evidence from Prior Work  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Eosinophil infiltrates</strong> reported in esophagectomy &amp; LES biopsies of achalasia patients (Spechler 2018).  </li>
<li style="margin-left: 0px;"><strong>Mast cell degranulation:</strong> Profound in LES muscle of achalasia (Nelson 2021).  </li>
<li style="margin-left: 0px;"><strong>Th2 cytokine effect:</strong> IL‑4Rα stimulation ↑ eotaxin‑3 secretion &amp; smooth‑muscle tension (Nelson 2024).  </li>
</ul>
</div></details>
<details><summary><strong>5.2 Epidemiologic Link  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Population study: Achalasia strongly associated with EoE and other allergic disorders (Reddy 2024).  </li>
<li style="margin-left: 0px;">Current cohort: 90 % EGJOO patients had atopy, supporting allergy‑mediated hypothesis.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>6. Clinical Implications &amp; Comparison to Standard Therapies  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Standard treatments:</strong> Pneumatic dilation, Heller myotomy, POEM – invasive, irreversible, may cause GERD, and efficacy wanes over time.  </li>
<li style="margin-left: 0px;"><strong>Potential advantage of steroids:</strong> Anti‑inflammatory therapy could reverse early allergic inflammation before neuronal loss, offering a reversible medical option.  </li>
</ul>
</div></details>
<details><summary><strong>7. Limitations &amp; Future Directions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>No control arm:</strong> Cannot exclude spontaneous EGJOO resolution; historic spontaneous remission rates 15‑74 % within 6 mo (pre‑CCv4.0 studies).  </li>
<li style="margin-left: 0px;"><strong>Sample size:</strong> n=10 limits statistical power; IRP normalized in only one patient.  </li>
<li style="margin-left: 0px;"><strong>Prednisone regimen:</strong> 20 mg × 14 days may be insufficient dose/duration for full reversal.  </li>
<li style="margin-left: 0px;"><strong>Inflammatory substrate variability:</strong> Not all EGJOO patients exhibited eosinophilic elevation; suggests heterogeneous pathogenesis.  </li>
</ul>
<details><summary><strong>7.1 Recommendations for Further Research  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Conduct randomized, placebo‑controlled trials with larger cohorts.  </li>
<li style="margin-left: 0px;">Explore higher prednisone doses or longer tapering schedules.  </li>
<li style="margin-left: 0px;">Investigate biomarkers (e.g., tissue eosinophil count, mast cell markers) to identify steroid‑responsive EGJOO phenotypes.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>8. Conclusions  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Two‑week prednisone course <strong>significantly lowered supine and upright IRP</strong> in a pilot EGJOO cohort.  </li>
<li style="margin-left: 0px;">Majority showed <strong>symptom score improvement</strong>, though mean changes were not statistically significant.  </li>
<li style="margin-left: 0px;">Findings <strong>support</strong> (but do not prove) that a subset of EGJOO may be <strong>allergy‑mediated, anti‑inflammatory responsive, and potentially reversible</strong>.  </li>
</ul>
</div></details>
<details><summary><strong>9. Discussion of Inflammatory Mechanisms  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Type 2 inflammation</strong> posited as muscle‑predominant EoE form affecting LES.  </li>
<li style="margin-left: 0px;">Activated eosinophils &amp; mast cells <strong>release mediators</strong> altering smooth‑muscle tone and destroying neurons.  </li>
</ul>
<details><summary><strong>9.1 Mast Cell Findings (Nelson 2021)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Profound degranulation observed in LES of achalasia patients.  </li>
</ul>
</div></details>
<details><summary><strong>9.2 Cytokine Effects (Nelson 2024)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Th2 cytokine signaling via IL‑4Rα ↑ eotaxin‑3 secretion → increased muscle tension.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>10. Safety, Funding &amp; Conflict Disclosures  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Funding:</strong> Baylor Scott &amp; White Research Institute.  </li>
<li style="margin-left: 0px;"><strong>Conflicts:</strong> Konda – Medtronic, Exact, Castle Biosciences, Pentax, Ambu; research funding Lucid Diagnostic. Souza, Spechler – consultants Phathom Pharma, Takeda, Castle Biosciences, Lucid Diagnostics.  </li>
</ul>
</div></details>
<details><summary><strong>11. Limitations of the Pilot Study (Expanded)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Control absence:</strong> No placebo group → cannot rule out spontaneous improvement.  </li>
<li style="margin-left: 0px;"><strong>Spontaneous resolution rates:</strong> Historical 15‑74 % within 6 mo (pre‑CCv4.0).  </li>
<li style="margin-left: 0px;"><strong>IRP trends:</strong> Significant ↓ but rarely normalized; dose/duration may be suboptimal.  </li>
</ul>
</div></details>
<details><summary><strong>12. Recommendations for Clinical Practice  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Consider short‑course prednisone for EGJOO patients with documented atopy/EoE.  </li>
<li style="margin-left: 0px;">Use as bridge before invasive therapies (pneumatic dilation, Heller myotomy, POEM).  </li>
</ul>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
